Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

post-transplant lymphoproliferative disease (PTLD) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

post-transplant lymphoproliferative disease

MONDO:0019088

Also known as:PTLD

Find Clinical TrialsTrials

Overview

Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)

TreatmentsNo approved treatments · 2 in pipeline

Clinical Trials19 registered · 6 recruiting

Diagnosis

Biomarker and diagnostic research for post-transplant lymphoproliferative disease has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for post-transplant lymphoproliferative disease. An additional 2 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for post-transplant lymphoproliferative disease, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for post-transplant lymphoproliferative disease. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Estimated prevalence: 1-5 in 10,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

19 clinical trials registered, 6 recruiting. Interventions under study include biologic therapy, drug therapy, procedural interventions, and other interventions. Pipeline includes 2 PHASE3, 4 PHASE2, 8 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:33 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:70568

GARD

Genetic and Rare Diseases Info Center

GARD:9553

Questions for Your Care Team

→Are any of the 19 active clinical trials a good fit for my situation?
→What is the current development status of nanatinostat and valganciclovir, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	66	42%
Research summaries	31	20%
Disease patterns and progression	23	15%
Clinical study results	12	8%
Laboratory research	9	6%
New treatment approaches	7	4%
Testing and diagnosis research	6	4%
Other research	2	1%

Kisho

post-transplant lymphoproliferative disease

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Clinicopathological landscape of pediatric monomorphic PTLD: national retrospective study.

Uncommon Presentation of a Rare Disease: Post-Transplant Lymphoproliferative Disorder in a Child Post Liver Transplant Presenting as Massive Splenomegaly.

Gastrointestinal-localized polymorphic post-transplant lymphoproliferative disorder following kidney transplantation after allogeneic hematopoietic stem cell transplantation: a rare case report.

post-transplant lymphoproliferative disease

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Clinicopathological landscape of pediatric monomorphic PTLD: national retrospective study.

Uncommon Presentation of a Rare Disease: Post-Transplant Lymphoproliferative Disorder in a Child Post Liver Transplant Presenting as Massive Splenomegaly.

Gastrointestinal-localized polymorphic post-transplant lymphoproliferative disorder following kidney transplantation after allogeneic hematopoietic stem cell transplantation: a rare case report.